ライフサイエンスコーパス: insulin-like

1 In isopods, the Insulin-like Androgenic Gland hormone (IAG) induces male

2 lf-sperm maintains the expression of a DAF-2 insulin-like antagonist, INS-37, which promotes the nucl

3 tide in cone-snail venom with moderate human insulin-like bioactivity.

4 synaptic function, could be preserved by the insulin-like effect of lipoic acid.

5 ed expression of a relaxin receptor, relaxin/insulin-like family peptide receptor 1 (RXFP1), in IPF f

6 One lying upstream of the relaxin/insulin-like family peptide receptor 2 ( RXP2) (chromoso

7 in adult males via interaction with relaxin/insulin-like family peptide receptor 2 (RXFP2).

8 backgrounds, including the long-lived daf-2/insulin like growth factor (IGF) receptor and short live

9 However, the possible roles of the insulin like growth factor-1 receptor (IGF-1R) on neuron

10 e regulation of insulin secretion by insulin/insulin-like growth factor (IGF) 2-AKT signaling.

11 The insulin-like growth factor (IGF) axis may be implicated

12 Insulin-like growth factor (IGF) binding protein 2 (IGFB

13 Signaling via the insulin-like growth factor (IGF) pathway is aberrantly a

14 Lowered insulin/insulin-like growth factor (IGF) signaling (IIS) can ext

15 Evolutionarily conserved insulin/insulin-like growth factor (IGF) signaling (IIS) has bee

16 hat maternal DR and reduced maternal insulin/insulin-like growth factor (IGF) signaling (IIS) increas

17 the sirtuin family of proteins, the insulin/insulin-like growth factor (IGF) signaling (IIS) pathway

18 The insulin/insulin-like growth factor (IGF) signaling pathway plays

19 Insulin-like growth factor (IGF) signaling plays an impo

20 study is the identification of mutations in insulin-like growth factor (IGF) signalling genes in 8/1

21 The insulin-like growth factor (IGF) system is a well-studie

22 The growth hormone and insulin-like growth factor (IGF) system is integral to h

23 , many of which display dysregulation of the insulin-like growth factor (IGF) system.

24 hlighted an enrichment of the "Regulation of Insulin-like Growth Factor (IGF) transport and uptake by

25 Cells were treated with T(3) (1.5 nm), insulin-like growth factor (IGF)-1 (1 mug mL(-1) ) or a

26 .0001), insulin (r(2) = 0.40, P < 0.005) and insulin-like growth factor (IGF)-1 (r(2) = 0.80, P < 0.0

27 -ERalphaKO along with higher serum levels of insulin-like growth factor (IGF)-1 as well as IGF-bindin

28 aintained the quiescent state by suppressing insulin-like growth factor (IGF)-mediated Akt-Tor and Er

29 Aberrant regulation of the insulin-like growth factor (IGF)/insulin (IIS)-PI3K-AKT-

30 growth factors (FGFs)-2 and -13, and type 1 insulin-like growth factor (IGF-1), which enhance neuron

31 A focus on reversible mechanisms identified Insulin-like growth factor (IGF1) deficiency with inadeq

32 Insulin-like growth factor 1 (IGF-1) administration incr

33 transcription factor, resulting in enhanced insulin-like growth factor 1 (IGF-1) expression and acti

34 Human insulin-like growth factor 1 (IGF-1) is a 70 amino acid

35 Insulin-like Growth Factor 1 (IGF-1) is associated with

36 Insulin-like growth factor 1 (IGF-1) is known to have di

37 The hormonal actions of insulin-like growth factor 1 (IGF-1) produced by the liv

38 that feeding-regulated hormones insulin and insulin-like growth factor 1 (IGF-1) reset circadian clo

39 t or energy levels-most notably, the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway,

40 nction through the regulation of the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway.

41 also requires nutritionally induced insulin/insulin-like growth factor 1 (IGF-1) signalling (IIS) vi

42 Finally, we studied the impact of insulin-like growth factor 1 (IGF-1) treatment on CDKL5

43 ng serum concentrations of glucose, insulin, insulin-like growth factor 1 (IGF-1), insulin-like growt

44 We previously established that an insulin-like growth factor 1 (IGF-1)-inducible mitochond

45 y, and low circulating levels of insulin and insulin-like growth factor 1 (IGF-1).

46 gate (MTA) showed an increased expression of insulin-like growth factor 1 (IGF-1).

47 o-expression of two soluble proteins, namely insulin-like growth factor 1 (IGF1) and osteopontin (OPN

48 sts expressed increased transcript levels of insulin-like growth factor 1 (Igf1) and the antimicrobia

49 lloprotease, Pappaa stimulates extracellular insulin-like growth factor 1 (IGF1) bioavailability.

50 ingly, treatment of RTT-derived neurons with Insulin-like Growth Factor 1 (IGF1) could rescue some of

51 novel MALDImmunoassay for quantification of insulin-like growth factor 1 (IGF1) in human plasma.

52 Insulin-like growth factor 1 (IGF1) is a key positive re

53 Insulin-like growth factor 1 (IGF1) is primarily synthes

54 Third, we uncovered that insulin-like growth factor 1 (IGF1) is produced by tumor

55 Insulin-like growth factor 1 (IGF1) is secreted in an au

56 AKT activation can be promoted by insulin-like growth factor 1 (IGF1) or insulin via a pat

57 proteins to autophosphorylation sites in the insulin-like growth factor 1 (IGF1) receptor (IGF1R).

58 ffects of (56)Fe radiation on adipokines and insulin-like growth factor 1 (IGF1) signaling axis in mo

59 Evidence suggests Insulin-like growth factor 1 (IGF1) signaling is involve

60 e neonatal airway where stromal cell-derived insulin-like growth factor 1 (IGF1) supports the prolife

61 Human fibroblast growth factor 2 (FGF2) and insulin-like growth factor 1 (IGF1), are canonical proto

62 Alveolar fibroblasts produced insulin-like growth factor 1 (IGF1), which instructed ex

63 n, or co-overexpression of osteopontin (OPN)/insulin-like growth factor 1 (IGF1)/ciliary neurotrophic

64 tic effects of potent growth factors such as insulin-like growth factor 1 and basic fibroblast growth

65 ands, and feet and are diagnosed by elevated insulin-like growth factor 1 levels and growth hormone l

66 f GH excess including significantly elevated insulin-like growth factor 1 levels, larger weight and b

67 bolism, such as suppression of production of insulin-like growth factor 1 or growth hormone, are invo

68 Supplementation of insulin-like growth factor 1 partially reverted the DR-i

69 atric skin display reduced activation of the insulin-like growth factor 1 receptor (IGF-1R) and alter

70 iates for the activation of PI3K by both the insulin-like growth factor 1 receptor (IGF-1R) and its c

71 Here, we found in the mouse that the insulin-like growth factor 1 receptor (IGF-1R) controls

72 rs revealed 6ha as preferential inhibitor of insulin-like growth factor 1 receptor (IGF-1R) in a pane

73 mice expressing a mutated form of the human insulin-like growth factor 1 receptor (IGF-1R) in skelet

74 We have previously shown that the insulin-like growth factor 1 receptor (IGF-1R) transloca

75 tor 2 (IGF2) gene, encoding a ligand for the insulin-like growth factor 1 receptor (IGF-1R), in a sub

76 ession in this lineage and was stimulated by insulin-like growth factor 1 receptor (IGF1R) activation

77 in asthma, but little is known about how the insulin-like growth factor 1 receptor (IGF1R) affects as

78 We demonstrate that the deletion of insulin-like growth factor 1 receptor (Igf1r) in mouse e

79 etibial myxoedema) involves the synergism of insulin-like growth factor 1 receptor (IGF1R) with TSHR

80 tent and functionally relevant activation of insulin-like growth factor 1 receptor (IGF1R), resulting

81 eduction of proangiogenic factors, including insulin-like growth factor 1 receptor (Igf1R).

82 we found that dual inhibition of MEK1/2 and insulin-like growth factor 1 receptor (IGF1R)/insulin re

83 nt mannose 6-phosphate receptor (CI-MPR) and Insulin-like growth factor 1 receptor (IGF1R); however,

84 al RKRR motif(2) from the alpha-chain of the insulin-like growth factor 1 receptor that is critical f

85 t-mammalian target of rapamycin pathway, and insulin-like growth factor 1 receptor-targeted therapy h

86 gans strains with mutations in daf-2/insulin/insulin-like growth factor 1 receptor.

87 Insulin-like growth factor 1 signaling in tenocytes is r

88 hanges in microRNA levels regulate SIRT1 and insulin-like growth factor 1 signalling.

89 IGF-1 (insulin-like growth factor 1) expression was increased a

90 indings included a protective role of IGF-1 (insulin-like growth factor 1) in systolic blood pressure

91 ar myocytes blocked phenylephrine- and IGF1 (insulin-like growth factor 1)-mediated RHEB induction, m

92 physiological hypertrophy induced by IGF-1 (insulin-like growth factor 1).

93 ion and loss-of-function mutations affecting insulin-like growth factor 1, fibroblast growth factor r

94 story, medications, and laboratory findings (insulin-like growth factor 1, follicle-stimulating hormo

95 Secondary outcomes included fasting insulin-like growth factor 1, lipids, glucose, insulin,

96 ne cardiomyocyte proliferation stimulated by insulin-like growth factor 1, this effect is mediated vi

97 model assessment of insulin resistance, and insulin-like growth factor 1.

98 pinal cord, and normalization of circulating insulin-like growth factor 1.

99 associated with higher mean levels of IGF1 (insulin-like growth factor 1; hazard ratio per 1 SD incr

100 mouse hippocampus, induces the expression of insulin-like growth factor 2 (IGF2) for the stabilizatio

101 nt hypomethylation of an enhancer within the insulin-like growth factor 2 (IGF2) gene in major psycho

102 s Network detected the overexpression of the insulin-like growth factor 2 (IGF2) gene, encoding a lig

103 We addressed this question at the H19/insulin-like growth factor 2 (Igf2) imprinted locus, the

104 Insulin-like growth factor 2 (IGF2) is the major fetal g

105 IMPs, also known as insulin-like growth factor 2 (IGF2) messenger RNA (mRNA)

106 Insulin-like growth factor 2 (IGF2) mRNA binding protein

107 activating enzyme, deiodinase-III (Dio3) and insulin-like growth factor 2 (Igf2), genes that are know

108 in the small dysfunctional placenta in FGR [insulin-like growth factor 2 knockout (P0) mouse model o

109 The gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2

110 f the heterochronic let-7 miRNA pathway, the insulin-like growth factor 2 mRNA-binding protein 1 (IGF

111 Insulin-like growth factor 2 mRNA-binding protein 1 (IGF

112 Insulin-like growth factor 2 mRNA-binding protein 1 (IGF

113 Global deletion of the mRNA-binding protein insulin-like growth factor 2 mRNA-binding protein 2 (IGF

114 Here, we determined that the RBP insulin-like growth factor 2 mRNA-binding protein 3 (IGF

115 Insulin-like growth factor 2 mRNA-binding proteins 1-3 (

116 Here we report that VKORC1v2 associates with insulin-like growth factor 2 receptor (IGF2R), also know

117 ion in mutants exhibiting aberrant H19/Igf2 (insulin-like growth factor 2) imprinting.

118 or necrosis factor alpha and lower levels of insulin-like growth factor 2.

119 ts known ability to promote the abundance of Insulin-like Growth Factor 2/IGF2, we find that IMP2 str

120 ing indicated substantial down-regulation of insulin-like growth factor binding protein (Igfbp) genes

121 Insulin-like growth factor binding protein (IGFBP)-1 inf

122 tor (PDGF) isoforms (PDGF-AA, -BB, and -AB), insulin-like growth factor binding protein (IGFBP)-2, an

123 Low circulating levels of insulin-like growth factor binding protein 1 (IGFBP-1) a

124 enes involved in embryonic neurodevelopment: insulin-like growth factor binding protein 2 ( IGFBP2),

125 Recent studies suggest that insulin-like growth factor binding protein 2 (IGFBP-2) m

126 Insulin-like growth factor binding protein 2 (IGFBP2) is

127 sulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3),

128 K regulates Runx1-dependent transcription of insulin-like growth factor binding protein 3 (IGFBP3), a

129 ase plasminogen activator receptor), IGFBP7 (insulin-like growth factor binding protein 7), and GDF-1

130 In this setting, the insulin-like growth factor binding protein IGFBP7 inhibi

131 Insulin-like growth factor binding protein-3 (IGFBP-3) b

132 hibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein-7 (IGFBP7) ha

133 Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)" ro

134 Circulating insulin-like growth factor I (IGF-I) is positively assoc

135 Insulin and insulin-like growth factor I (IGF-I) signal through the

136 Disruption of insulin-like growth factor I (IGF-I) signaling is a key

137 wel disease (IBD) present with reduced serum insulin-like growth factor I (IGF-I).

138 ition and height growth, perhaps mediated by insulin-like growth factor I (IGF-I).

139 release of growth hormone and, consequently, insulin-like growth factor I (IGF1), most often by a pit

140 Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pa

141 Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new

142 ved growth factor receptor beta (Pdgfrb) and insulin-like growth factor I receptor (Igf1r) on T-ALL c

143 ata from a candidate marker, we analyzed the insulin-like growth factor I receptor (IGF1R), a promisi

144 human epidermal growth factor, insulin, and insulin-like growth factor I, particularly at the parasi

145 bolic variables, including glucose, insulin, insulin-like growth factor I, triglycerides, cholesterol

146 e gene that experiences LOI is the paracrine insulin-like growth factor IGF2, which occurs commonly i

147 a systemic administration of the polypeptide insulin-like growth factor II (IGF-II) reverses all thes

148 st the effects of systemic administration of insulin-like growth factor II (IGF-II), a polypeptide th

149 Insulin-like growth factor II (IGF2) enhances memory in

150 antagomir-352 up-regulated the expression of insulin-like growth factor II receptor (IGF2R), which ma

151 Type 1 insulin-like growth factor receptor (IGF1R) is a recepto

152 Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Epide

153 the MAPK pathway, PI3Kbeta, and PI3Kalpha or insulin-like growth factor receptor 1 (IGF1R) synergisti

154 RBB4 while revealing increased expression of insulin-like growth factor receptor 1 (IGF1R).

155 4 seems to exert RIBEs by acting through the insulin-like growth factor receptor DAF-2.

156 oward the insulin receptor and/or the type 1 insulin-like growth factor receptor.

157 Reduced activity of insulin/insulin-like growth factor signaling (IIS) and mechanist

158 o DNA damage repair, cell cycle progression, insulin-like growth factor signaling, innate immunity, a

159 etabolic diseases and cancer are insulin and insulin-like growth factor signalling pathways.

160 nt mannose-6-phosphate receptor, also called insulin-like growth factor two receptor (CIM6P/IGF2R), p

161 inases, including the highly cancer relevant insulin-like growth factor type 1 receptor (IGF-1R).

162 Insulin-like growth factor type 2 (IGF2) receptor (IGF2R

163 MSCs exhibited >25x higher secretion of IGF (insulin-like growth factor)-1 compared with failing hMSC

164 growth while suppressing the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

165 In addition to IRBP, the IPM also contains insulin-like growth factor-1 (IGF-1) and its associated

166 scular endothelial growth factor-A (VEGF-A), insulin-like growth factor-1 (IGF-1) and Klotho, in the

167 Insulin-like growth factor-1 (IGF-1) and signal transduc

168 recurrent GBM, driven by macrophage-derived insulin-like growth factor-1 (IGF-1) and tumor cell IGF-

169 ransforming Growth Factor Beta (TGFbeta) and insulin-like growth factor-1 (IGF-1) are known to promot

170 e previously shown that systemic infusion of insulin-like growth factor-1 (IGF-1) exerts anti-inflamm

171 (PFNA), may alter levels of sex hormones and insulin-like growth factor-1 (IGF-1) in animals.

172 High circulating insulin-like growth factor-1 (IGF-1) levels increase the

173 Activation of insulin-like growth factor-1 (IGF-1) receptor (IGF1R) si

174 In contrast, mice pretreated with insulin-like growth factor-1 (IGF-1) showed resolution o

175 mediates adipogenesis and show a link to the insulin-like growth factor-1 (IGF-1) signaling pathway.

176 VEGF-D), ETS-related gene protein (ERG), and insulin-like growth factor-1 (IGF-1) were measured simul

177 Interestingly, (1-3) insulin-like growth factor-1 (IGF-1), a small peptide un

178 eride) (PEAD) polycation, heparin, and cargo insulin-like growth factor-1 (IGF-1), in thiolated gelat

179 ker proteins ETS-related gene protein (ERG), insulin-like growth factor-1 (IGF-1), pigment epithelial

180 elaborates the cardioprotective polypeptide, insulin-like growth factor-1 (IGF-1), which activates IG

181 Lin28-treated retinas responded to insulin-like growth factor-1 (IGF1) by initiating retina

182 actors released by astrocytes as insulin and insulin-like growth factor-1 (IGF1).

183 secretion of paracrine mediators, including insulin-like growth factor-1 (IGF1).

184 d-beta plaques and expressed 3.2-fold higher insulin-like growth factor-1 (P < 0.01) and ~60% lower t

185 , SP and its metabolites in combination with insulin-like growth factor-1 are shown to promote the co

186 Perfluoroalkyl substances, sex hormones, and insulin-like growth factor-1 at 6-9 years of age: a cros

187 gonists which led to a sustained increase of insulin-like growth factor-1 in a dog pharmacodynamic st

188 Macrophage-derived insulin-like growth factor-1 is a key neurotrophic and n

189 Insulin-like growth factor-1 levels in quartile 4 were n

190 Insulin-like growth factor-1 levels in quartile 4 were n

191 hormone secretion and subsequent increase of insulin-like growth factor-1 levels, an important mediat

192 anslocation to the nucleus was stimulated by insulin-like growth factor-1 or TGFbeta.

193 Elevated IGF-1/insulin-like growth factor-1 receptor (IGF-1R) autocrine

194 feration in P2 cardiomyocytes, by activating insulin-like growth factor-1 receptor (IGF-1R)-mediated

195 -regulation of two of its targets: BCL-2 and insulin-like growth factor-1 receptor (IGF1R).

196 kinases (RTK), including the cancer-relevant insulin-like growth factor-1 receptor (IGF1R).

197 mmunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically

198 of the prefusion RSV-F glycoprotein with the insulin-like growth factor-1 receptor, triggers the acti

199 agy gene, and observed deficient insulin and insulin-like growth factor-1 signaling.

200 Impaired insulin/insulin-like growth factor-1 signalling (IGF-1) and insu

201 acronutrients, milk contains calcium and the insulin-like growth factor-1 that are of major relevance

202 -6 and -10, tumor necrosis factor-alpha, and insulin-like growth factor-1 were not found to be associ

203 2 saturation and plasma glucose, insulin and insulin-like growth factor-1 were positively associated

204 IGF-1 (insulin-like growth factor-1) is markedly decreased in n

205 (lipid X receptor), the growth factor IGF1 (insulin-like growth factor-1), and the splenic red pulp

206 or-alpha), pro-healing immune profiles (high insulin-like growth factor-1, elongated cell morphology)

207 LR2 deficiency also affected milk content of insulin-like growth factor-1, IFN-gamma, IL-6, and IL-13

208 changes including altered levels of insulin, insulin-like growth factor-1, leptin, adiponectin, stero

209 emoattractant protein-1, IL-6, IL-1beta, and insulin-like growth factor-1.

210 5190457 were acyl-to-total ghrelin ratio and insulin-like growth factor-1.

211 IMP3 (insulin-like growth factor-2 mRNA binding protein 3) is

212 The consistent surface overexpression of insulin-like growth factor-2 receptor (IGF2R) has been r

213 The cation-independent mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R or IGF2

214 acellular domains of the mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R), domai

215 sion, including an increase in stress marker insulin-like growth factor-binding protein 1 (IGFBP-1),

216 esponse elements located in the promoters of insulin-like growth factor-binding protein 1 (IGFBP1) an

217 ated with higher mean levels of both IGFBP1 (insulin-like growth factor-binding protein 1; hazard rat

218 ein 4, Plasminogen activator inhibitor 1 and Insulin-like growth factor-binding protein 2) with a pre

219 aminoacylase-1, growth hormone receptor, and insulin-like growth factor-binding protein 2.

220 sure; cFn (cellular fibronectin) and IGFBP3 (insulin-like growth factor-binding protein 3) were relat

221 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 ([TIMP-2] x

222 r, tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 and of rena

223 of tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 and renal r

224 tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 in response

225 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in this pop

226 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 results in

227 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 test was no

228 nd tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 to predict

229 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was 0.84 (0

230 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was measure

231 ry tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 was not sig

232 of tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 was poor wi

233 ry tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 was unable

234 owed by a marker of cell cycle arrest (urine insulin-like growth factor-binding protein 7) and, final

235 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] across the

236 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] and signif

237 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] between pr

238 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] changes an

239 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] increases

240 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] were signi

241 RNA-seq analysis identified insulin-like growth factor-binding protein-5 (IGFBP-5) a

242 cancer model and decreased the expression of insulin-like growth factor-binding protein-5 (IGFBP5).

243 [C-telopeptide for type I collagen], IGFBP7 [insulin-like growth factor-binding protein-7], and GAL-3

244 GFBP)-1 influences fetal growth by modifying insulin-like growth factor-I (IGF-I) bioavailability.

245 l and neuropsychological recovery, and serum insulin-like growth factor-I (IGF-I) may mediate this ef

246 In the total population, insulin-like growth factor-I (IGF-I)-enhanced cell cycle

247 rafts in mice, along with reduction of tumor insulin-like growth factor-I and vascular endothelial gr

248 ile hormone, 20-hydroxyecdysone, and insulin/insulin-like growth factor-like signaling in regulating

249 clock function and elevated transcription of Insulin-like Growth Factor2 (Igf2).

250 ance of pancreatic cancer cells by secreting insulin-like growth factors (IGF) 1 and 2, which activat

251 Insulin-like growth factors (IGFs) are essential for loc

252 This review discusses the role of the insulin-like growth factors (IGFs) in controlling placen

253 Insulin-like growth factors (IGFs), specifically IGF1 an

254 Information on how insulin and insulin-like growth factors 1 and 2 (IGF-1 and -2) activ

255 and structural homology between mature human insulin-like growth factors IGF-1 and IGF-2 makes serolo

256 The insulin-like growth factors IGF1 and IGF2 are closely re

257 Hyperinsulinemia and higher insulin-like growth factors may increase breast cancer r

258 s of the transforming growth factor-beta and insulin-like growth factors pathways, and extracellular

259 P94), a prominent ER chaperone known to fold insulin-like growth factors, in proinsulin handling with

260 ng roles for cancer progression, such as the insulin-like growth factors.

261 itro, resulting in higher bioavailability of insulin-like growth factors.

262 inflammation markers after meal; for example insulin-like hormone FGF-19 levels were elevated at 240

263 Relaxin, an insulin-like hormone, suppresses atrial fibrillation, in

264 In well-fed males, insulin-like (insulin/IGF-1 signaling [IIS]) and transfo

265 ia lack the mammal-specific affinity between insulin-like ligands and M6PR.

266 Cone snails have evolved a variety of insulin-like molecules that may help with the developmen

267 nked ins-9 gene, which encodes a new agonist insulin-like peptide (ILP) expressed specifically in the

268 Here, we show that one specific subtype of insulin-like peptide (ILP) responds to nutrient status a

269 ally regulating the expression of a specific insulin-like peptide (ILP), INS-6.

270 g cells to trigger the release of Drosophila insulin-like peptide 2 (dilp2) and the other extends to

271 thway revealed elevated levels of Drosophila insulin-like peptide 2 (Dilp2) in the IPCs and elevated

272 Insulin-like peptide 3 (INSL3) is a member of the relaxi

273 Insulin-like peptide 5 (INSL5) has recently been discove

274 xogenous application of a single recombinant insulin-like peptide cloned from the Aplysia CNS cDNA re

275 n identified distinct peptides that regulate insulin-like peptide expression, feeding behavior, or bo

276 Recently, we described a monomeric, insulin-like peptide in cone-snail venom with moderate h

277 Further we show that insulin-like peptide receptor (INSR) and forkhead box pr

278 AWC-AIA temperature responses requires INS-1 insulin-like peptide signaling from the gut and DAF-16/F

279 We found that decima influences insulin-like peptide transcription in the GABA receptor

280 cts basal levels of INS-7, an ageing-related insulin-like peptide, which acts in the intestine to det

281 ong-lived dietary restricted fruit flies and insulin-like-peptide mutants exhibit small nucleoli and

282 IIS models, namely Drosophila lacking three insulin-like peptides (dilp2-3,5(-/-)) and mice lacking

283 Of the 7 Drosophila insulin-like peptides (Dilps), we find that Dilp-2 is re

284 ere, we report that the regulated release of insulin-like peptides (ILPs) during development of the C

285 male-female differences in the production of insulin-like peptides (Ilps) from the IPCs do not appear

286 , we show that expression of many Drosophila insulin-like peptides (ILPs) is reduced in mon1 mutants

287 ing depends on the balanced signaling of two insulin-like peptides (ILPs), INS-16 and INS-4, which ac

288 In silico target prediction identified that insulin-like peptides 7 and 8 (ilp7 and ilp8) are putati

289 in, we show that in Drosophila expression of insulin-like peptides is regulated by neprilysin activit

290 involved in homeostatic control, and express insulin-like peptides with well-established roles in reg

291 response to photoreceptor-EGF, glia produce insulin-like peptides, which induce lamina neuronal diff

292 coupling pheromone sensing to signaling via insulin-like peptides.

293 ng those that secrete some of the Drosophila insulin-like peptides.

294 ornutus ILP (GcorILP1-5) and two G. cornutus insulin-like receptor (GcorInR1, -2) genes in the G. cor

295 y to promote somatic differentiation through Insulin-like receptor (InR) activation.

296 rine signaling pathways, including the DAF-2/insulin-like receptor signaling pathway [3-7].

297 espan extension via the suppression of IGF-1/insulin-like signaling (IIS) offers a possibility to ret

298 n as dauer by inhibiting the conserved DAF-2 insulin-like signaling (ILS) pathway through incompletel

299 Bivalent antireceptor antibodies can elicit insulin-like signaling by mutant INSR in cultured cells,

300 that are mediated by the endogenous Aplysia insulin-like system.